Metabolism of Antituberculosis Drugs in HIV-Infected Persons With Tuberculosis

• Status: Completed
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine if a relationship exists between the level of antituberculosis drugs (isoniazid, rifampin, ethambutol, and pyrazinamide) in the blood and the outcome of HIV-positive patients with tuberculosis. This study also evaluates how these drugs are absorbed and metabolized in the body.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
• Treatments: Antitubercular Agents; Ethambutol; Isoniazid; Pyrazinamide; Pyridoxal; Pyridoxine; Rifampin; Vitamin B 6

Criteria

Inclusion Criteria

You may be eligible for this study if you:

• Are HIV-positive and have tuberculosis.

• Are 13 years of age or older.

• Have written, informed consent of parent or guardian if you are under 18 years of age.

• Agree to practice abstinence or use barrier methods of birth control during the study.

Exclusion Criteria

You will not be eligible for this study if you:

• Have any other disorder or condition which might cause study treatment to be undesirable.

• Are pregnant.